Cargando…
Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that target downregulators of the anti-cancer immune response: cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand PD-L1. ICPIs are now approved for the treatment of a wide array of malignancies, with rates...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143593/ https://www.ncbi.nlm.nih.gov/pubmed/30228268 http://dx.doi.org/10.1038/s41424-018-0049-9 |
_version_ | 1783355996520841216 |
---|---|
author | Reddy, Haritha G. Schneider, Bryan J. Tai, Andrew W. |
author_facet | Reddy, Haritha G. Schneider, Bryan J. Tai, Andrew W. |
author_sort | Reddy, Haritha G. |
collection | PubMed |
description | Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that target downregulators of the anti-cancer immune response: cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand PD-L1. ICPIs are now approved for the treatment of a wide array of malignancies, with rates of durable responses in the metastatic setting far exceeding what would be expected from conventional chemotherapy. ICPIs have also been associated with rare but serious immune-related adverse events due to over-activation of the immune system that can affect any organ, including the gastrointestinal tract and liver. As the use of ICPIs in oncology continues to increase, ICPI-associated colitis and hepatitis will be encountered frequently by gastroenterologists and hepatologists. This review will focus on the diagnosis and management of ICPI-associated colitis and hepatitis. We will also compare these ICPI-related toxicities with sporadic inflammatory bowel disease and autoimmune liver disease. |
format | Online Article Text |
id | pubmed-6143593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-61435932018-09-21 Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis Reddy, Haritha G. Schneider, Bryan J. Tai, Andrew W. Clin Transl Gastroenterol Review Article Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that target downregulators of the anti-cancer immune response: cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand PD-L1. ICPIs are now approved for the treatment of a wide array of malignancies, with rates of durable responses in the metastatic setting far exceeding what would be expected from conventional chemotherapy. ICPIs have also been associated with rare but serious immune-related adverse events due to over-activation of the immune system that can affect any organ, including the gastrointestinal tract and liver. As the use of ICPIs in oncology continues to increase, ICPI-associated colitis and hepatitis will be encountered frequently by gastroenterologists and hepatologists. This review will focus on the diagnosis and management of ICPI-associated colitis and hepatitis. We will also compare these ICPI-related toxicities with sporadic inflammatory bowel disease and autoimmune liver disease. Nature Publishing Group US 2018-09-19 /pmc/articles/PMC6143593/ /pubmed/30228268 http://dx.doi.org/10.1038/s41424-018-0049-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Reddy, Haritha G. Schneider, Bryan J. Tai, Andrew W. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis |
title | Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis |
title_full | Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis |
title_fullStr | Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis |
title_full_unstemmed | Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis |
title_short | Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis |
title_sort | immune checkpoint inhibitor-associated colitis and hepatitis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143593/ https://www.ncbi.nlm.nih.gov/pubmed/30228268 http://dx.doi.org/10.1038/s41424-018-0049-9 |
work_keys_str_mv | AT reddyharithag immunecheckpointinhibitorassociatedcolitisandhepatitis AT schneiderbryanj immunecheckpointinhibitorassociatedcolitisandhepatitis AT taiandreww immunecheckpointinhibitorassociatedcolitisandhepatitis |